The invention is a transdermal patch containing a noradrenergic and specific serotonergic antidepressant (NaSSA) such as mirtazapine or the like as the active ingredient therein and capable of transdermally and quantitatively administering the active ingredient. Further, the transdermal patch of the invention exhibits a sufficient therapeutical effect, can suppress side effects that are problematic in oral administration and improves patient compliance and quality of life (QOL), and can solve various problems. Preferably and the patch provided by the invention contains the active ingredient in an amount of from 2 to 30% by mass relative to the drug-containing layer.
